NCT06196567 Pulsed Electromagnetic Field Therapy on Muscle Strength and Function in Patients With End-stage of Knee Osteoarthritis
| NCT ID | NCT06196567 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Chinese University of Hong Kong |
| Condition | Knee Osteoarthritis |
| Study Type | INTERVENTIONAL |
| Enrollment | 43 participants |
| Start Date | 2024-01-01 |
| Primary Completion | 2026-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 43 participants in total. It began in 2024-01-01 with a primary completion date of 2026-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
End-stage OA knee is one of the most common musculoskeletal complaints, with over 34,000 patients waiting for joint replacement in Hong Kong and is expected to increase as the population continues to age constantly. The nominal waiting time for joint replacement in Hong Kong is long compared with many developed countries, averaging at 122 months, resulting in many elderly patients living with severe pain, limiting their daily activities. We are, therefore, in dire need to improve the well-being of this large and increasing group of patients as the capacity for operations remains limited. It is important to maintain preoperative knee-extensor strength in the end-stage of knee OA awaiting TKR because the improvement of knee-extensor strength may postpone the need for surgery and increase the ability to perform functional activities after TKR at the same time. PEMF exposure, on top of regular exercise training, may promote the secretion of myokine and in turn, promote muscle regeneration. These findings laid grounds for implementing PEMF treatment for end-stage knee OA patients to enhance muscle regeneration in periods with limited physical activity. The novelty of this study is that this is the first RCT to examine if pulsed electromagnetic field therapy (PEMF), in addition to a standard rehabilitation, produces better muscle strength and functional performance before and after TKR in people with knee OA than either intervention alone. The impact of this study is particularly strong given end-stage patients waiting for knee replacement surgeries in Hong Kong.
Eligibility Criteria
Inclusion Criteria: * Male and female patients end-stage knee OA over 50 waiting for TKR * Patient has been scheduled for TKR at Prince of Wales Hospital * Able to comply with the assessments and has given oral and written consent Exclusion Criteria: * Patients with connective tissue disorders or myositis condition * History of any Hip \& Knee joint replacement * Patients with acute immobility (i.e., post hip fracture or post-acute hospital admission) * Previous cases of any substances abuse * Patients already had TKR for one knee before * Patients are unable to transport themselves for intervention * Patients have any neuromuscular or neurodegenerative conditions * Patients have the history of inflammatory arthritis
Contact & Investigator
Michael Tim-Yun Ong
PRINCIPAL INVESTIGATOR
Chinese University of Hong Kong
Frequently Asked Questions
Who can join the NCT06196567 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, up to 100 Years, studying Knee Osteoarthritis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06196567 currently recruiting?
Yes, NCT06196567 is actively recruiting participants. Contact the research team at michael.ong@cuhk.edu.hk for enrollment information.
Where is the NCT06196567 trial being conducted?
This trial is being conducted at Hong Kong, Hong Kong.
Who is sponsoring the NCT06196567 clinical trial?
NCT06196567 is sponsored by Chinese University of Hong Kong. The principal investigator is Michael Tim-Yun Ong at Chinese University of Hong Kong. The trial plans to enroll 43 participants.